Loading...

NEXTGEN METASTATIC HR+ BREAST CANCER PANEL

image not found

NABL Cap Accredited 
The NextGen Metastatic HR+ Breast Cancer Panel at Metropolis Healthcare is a comprehensive molecular test designed for hormone receptor–positive metastatic breast cancer patients. This panel evaluates key somatic mutations, gene amplifications, and other genomic alterations to guide targeted therapy and personalized treatment planning. Metropolis Healthcare uses high-depth Next-Generation Sequencing and validated bioinformatics pipelines to provide precise, clinically actionable results. It is ideal for patients with advanced breast cancer requiring detailed molecular insights to optimize therapy selection.

  • 17 Crores+ Samples Processed
  • World Class Technology Labs
  • 25+ Years of Trust & Experience
  • Free Home Collection

Price: Rs. 45,000.00

Sample Type: Tissue

Fasting Not Required


Notes:N8297

Frequently Asked Questions (FAQ's):

What does the Metastatic HR+ Breast Cancer Panel at Metropolis Healthcare include?
It analyzes key genes associated with metastatic HR+ breast cancer, including mutations and amplifications relevant for targeted therapy.

How does Metropolis Healthcare perform this breast cancer panel?
Metropolis Healthcare uses high-depth NGS and validated bioinformatics workflows to ensure accurate and clinically actionable genomic profiling.

Who should consider taking this test at Metropolis Healthcare?
Patients with hormone receptor–positive metastatic breast cancer needing molecular insights for therapy optimization should consider this panel.

Is fasting required for the Metastatic HR+ Breast Cancer Panel at Metropolis Healthcare?
No fasting is required; tumor tissue or blood samples are used as advised by the clinician.

How long do results take at Metropolis Healthcare?
Results typically take 2–3 weeks due to detailed sequencing and variant interpretation.

Can this test at Metropolis Healthcare help guide targeted therapy decisions?
Yes, it identifies actionable mutations and amplifications to support personalized treatment planning.

How accurate is the NGS analysis performed by Metropolis Healthcare?
Metropolis Healthcare ensures high accuracy through deep sequencing coverage and stringent quality control protocols

Does this panel support long-term breast cancer management at Metropolis Healthcare?
Yes, the molecular insights help clinicians plan therapy, monitor progression, and optimize long-term management for HR+ metastatic breast cancer.

 
 

OUR corporates PARTNER

Feedback

Patient's Testimonials

Trusted by Thousands

OUR Accreditations

OUR Lab